Albain KSBarlow WEShak S. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65.
- Search Google Scholar
- Export Citation
)| false . , Albain KS , Barlow WE , Shak S Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. 2010; 11: 55– 65.
Dowsett MCuzick JIngle J. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509–518.
Jasem JFisher CMAmini A. The 21-gene recurrence score assay for node-positive, early-stage breast cancer and impact of RxPONDER trial on chemotherapy decision-making: have clinicians already decided? J Natl Compr Canc Netw 2017;15:494–503.
Roberts MCWeinberger MDusetzina SB. Racial variation in the uptake of Oncotype DX testing for early-stage breast cancer. J Clin Oncol 2016;34:130–138.
de Boer RHBaker CSpeakman D. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Med J Aust 2013;199:205–208.
Yamauchi HNakagawa CTakei H. Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer. Clin Breast Cancer 2014;14:191–197.
Bargallo JELara FShaw-Dulin R. A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital. J Surg Oncol 2015;111:203–207.
Eiermann WRezai MKümmel S. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013;24:618–624.
Gligorov JPivot XBJacot W. Prospective clinical utility study of the use of the 21-gene assay in adjuvant clinical decision making in women with estrogen receptor-positive early invasive breast cancer: results from the SWITCH study. Oncologist 2015;20:873–879.
Lee MHHan WLee JE. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea. Cancer Res Treat 2015;47:208–214.
Oratz RKim BChao C. Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract 2011;7:94–99.
Torres STrudeau MGandhi S. Prospective evaluation of the impact of the 21-gene recurrence score assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada. Oncologist 2018;7:768–775.
Sun JFenton DBaxter S. A prospective clinical utility study of the impact of the 21-gene recurrence score (RS) assay in the treatment of estrogen receptor positive (ER+) HER2 negative (HER2-) 1-3 node positive (N+) breast cancer (BC). Presented at the 2017 San Antonio Breast Cancer Symposium; December 5−9 2017; San Antonio Texas.
Kurian AWBondarenko IJagsi R. Recent trends in chemotherapy use and oncologists’ treatment recommendations for early-stage breast cancer. J Natl Cancer Inst 2018;110:493–500.
Stemmer SMSteiner MRizel S. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. NPJ Breast Cancer 2017;3:32.
Roberts MCMiller DPShak S. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat 2017;163:303–310.
Nitz UGluz OChristgen M. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017;165:573–583.
- Search Google Scholar
- Export Citation
)| false . , Nitz U , Gluz O , Christgen M Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. 2017; 165: 573– 583.
Gluz ONitz UChristgen N. Prospective WSG phase III PlanB trial: clinical outcome at 5-year follow up and impact of 21 Gene Recurrence Score result central/local-pathological review of grade ER PR and Ki67 in HR+/HER2- high risk node-negative and –positive breast cancer. Presented at the 2016 European Breast Cancer Conference; March 9−11 2016; Amsterdam the Netherlands.
Petkov VIMiller DPHowlader N. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer 2016;2:16017.
Shak SMPetkov VI. Breast cancer-specific mortality (BCSM) in patients with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice. Presented at the 2017 San Antonio Breast Cancer Symposium; December 5−9 2017; San Antonio Texas.
Gradishar WJAnderson BOBalassanian R. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2015. Accessed September 12 2018. To view the most recent version visit NCCN.org.
Cronin KPVHowlader NHowe W. Dissemination of 21-gene assay testing among female breast cancer patients in the US. Presented at the 2016 American Society of Clinical Oncology Annual Meeting; June 3−7 2016; Chicago Illinois.
Roberts MCBryson AWeinberger M. Oncologists’ barriers and facilitators for Oncotype Dx use: qualitative study. Int J Technol Assess Health Care 2016;32:355–361.
Lieu TARay GTPrausnitz SR. Oncologist and organizational factors associated with variation in breast cancer multigene testing. Breast Cancer Res Treat 2017;163:167–176.
Reeder-Hayes KEWheeler SBBaggett CD. Influence of provider factors and race on uptake of breast cancer gene expression profiling. Cancer 2018;124:1743–1751.